{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-341239","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-08-10T11:19:57+00:00","discovered_at":"2026-08-10T11:25:00.430079+00:00","generated_at":"2026-08-10T11:25:06.754733+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"AbbVie to acquire Apogee for $135.11/share (~$10.9B); Q2 results reported","bullets":["AbbVie to acquire Apogee for $135.11/share cash, ~$10.9B equity value; expected close Q3 2026.","Phase 2 APEX Part B met endpoints: 65.9% EASI-75 (41.9% placebo-adjusted) with mid-dose zumilokibart.","Cash $1.3B at June 30, 2026; Q2 net loss $85.9M vs $66.1M year ago.","Blackstone financing collaboration up to $1.3B non-dilutive for zumilokibart development.","Phase 3 initiation for zumilokibart in atopic dermatitis planned this year; EoE and asthma trials set."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-341239","json":"https://secwatch.observer/filing/0001193125-26-341239.json","markdown":"https://secwatch.observer/filing/0001193125-26-341239.md","text":"https://secwatch.observer/filing/0001193125-26-341239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000119312526341239/0001193125-26-341239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000119312526341239/apge-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:25:06.754733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}